Prevention of disseminated Mycobacterium avium complex (MAC) disease in advanced HIV infection.
≥18yrs: 300mg once daily. If inclined to GI upset, may give 150mg twice daily with food. Severe renal impairment (CrCl <30mL/min), concomitant indinavir or nelfinavir: reduce rifabutin dose by 50%.
<18yrs: not recommended.
Active tuberculosis: do not administer. Evaluate and test for tuberculosis before and during therapy; treat with combination antituberculosis regimen if active disease occurs. Do hematologic tests periodically. Renal insufficiency. May stain body secretions and contact lenses. Elderly. Pregnancy (Cat.B). Nursing mothers.
Antagonizes dapsone, sulfamethoxazole-trimethoprim, indinavir, nelfinavir, zidovudine, oral contraceptives (change or use additional nonhormonal birth control methods) or drugs that are metabolized by CYP3A enzymes (eg, itraconazole, clarithromycin, saquinavir). Potentiated by CYP3A inhibitors (eg, fluconazole, clarithromycin). Concomitant delavirdine, ritonavir: not recommended.
Discolored urine, GI upset, abdominal pain, dyspepsia, fever, myalgia, rash, taste perversion, neutropenia, thrombocytopenia, leukopenia; rare: myositis, uveitis.